 |
Clariant has recently announced a successful completion of its long-standing expansion project at its Lewiston (Maine, USA) facility. With activation of a new high-efficient extrusion line as well as some auxiliary equipment, the productive capacity of this site is now 40% larger.
The core of the new line is a twin-screw extruder designed for mass-batch production (up to 6000 kg or larger) of pre-colored medical-grade polymer compounds under Clariant's MEVOPUR brand. The list of auxiliary equipment includes material handling systems, weighing stations along with additional water-cooling capacity.
To preserve flexibility in terms of possible batch sizes as well as an ability to meet special requirements, Clariant will further maintain and promote its existing small extrusion lines like the one completed last year at the same site. This is very important first of all for pharmacological companies as many resin manufacturers decided to cancel small-batch servicing.
Lewiston plant up-to-date capabilities were presented last week at MD&M West trade show in Anaheim, California by Clariant's experts' team.
The other two Clariant's manufacturing plants focusing on medical-grade polymers for both devices and special packaging are located in Sweden and Singapore.
